RxDoctor Payments Data

Dorothy Nicholson, MD

Rheumatology · Alexandria, VANPI 1033298138

Payments from drug & device makers

$635in general payments, 2019–2025

Across 18 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$239
  • Amgen$159
  • Aurinia Pharma U.S., Inc.$102
  • AbbVie$21
  • Radius Health, Inc.$19
  • Merck$17
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$61497%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 30th percentile of 159 rheumatology providers in Virginia.

See all rheumatology providers in Virginia

Medicare billing

Part B allowed, 2024
$468,025
Medicare patients
386
Services billed
38,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept37$555,848
EnbrelEtanercept27$255,076
Humira PenAdalimumab22$211,457
Humira(Cf) PenAdalimumab18$176,605
Teriparatide39$72,980
ForteoTeriparatide12$49,850
OxycontinOxycodone Hcl14$22,804
ActemraTocilizumab13$16,366
MethotrexateMethotrexate Sodium178$6,145
Hydroxychloroquine Sulfate116$3,397
Risedronate Sodium15$2,163
Prednisone177$2,078
Allopurinol81$1,664
Mycophenolate Mofetil13$1,585
Cevimeline Hcl15$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$159$255,07627 claims
Lilly USA, LLCForteo$17$49,85012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 159 rheumatology providers in Virginia.

Other rheumatology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →